With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...
Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...
BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...